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Abstract
Cardiac Progenitor Cells (CPCs) are multipotent cells of the myocardium. They are located inside niches of the 
heart muscle, can be isolated, characterized and used for cardiac regeneration in stem cell therapy. Actually, CPCs 
may be isolated by tissue digestion with or without cell sorting, but it is difficult to achieve the maximum level of 
differentiation when these cells are implanted into a damaged myocardium. 
The knowledge recently acquired on small molecules of non-coding RNAs, microRNA (miRNA), may improve 
the use of these cells in stem cell therapy. In fact, these small molecules may be attached to devices or adminstered 
as they are or in combination with nanoparticles in order to drive the correct differentiation of stem cells. Regarding 
heart regeneration, we can acquire knowledge from the role of miRNAs in heart development and use it to reprogram 
CPCs to gain the correct three-dimensional structure of the cardiac muscle. 
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Introduction
MicroRNAs (miRNAs) are short endogenous single-strand 
RNA molecules (21- 23 nucleotides in length) that have an effect in 
controlling gene expression.
miRNAs were described, for the first time, in 1993 in Caenorhabditis 
elegans by Lee and colleagues. The authors found a small non-coding 
RNA, called lin-4, which was able to inhibit the translation of lin-14 
mRNA during the larval development [1]. However, this finding came 
out from many studies performed in Caenorhabditis elegans starting 
from 1981, when Chalfie and colleagues found a loss of function 
mutation in the gene of lin-4 which led to a constitutive expression of 
larval-specific genes [2]. Eight years later, another group of researchers 
demonstrated that lin-4 was able to inhibit the expression of two genes, 
lin-14 and lin-28, involved in the larva-to-adult developmental switch 
[3]. Later, in 1991, through deletion experiments, it was found that the 
interaction between lin-4 and lin-14 was required to down-regulate 
lin-14 protein levels during development [4]. Finally, thanks to these 
discoveries, in 1993, Lee and colleagues described lin-4 as a small-
non coding RNA which was a negative regulator of lin-14 mRNA; the 
authors also found that Lin-4 RNA sequences were complementary 
to the 3’untranslated region of the lin-14 messenger, suggesting a 
potential specific-sequence interaction [1]. 
Some years later, the discovery of another non-coding small 
RNA, allowed the development of the research field on miRNAs. In 
a study performed in 2000 by Reinhart and colleagues, a small RNA 
(21-nucleotides in length), let-7, was described as a regulatory RNA 
highly conserved among the species [5]. This finding opened the way to 
other studies that finally recognized the class of small non-coding RNA 
as a novel class of regulators for gene expression, called miRNAs [6].
At present, for studies on miRNAs, scientists use a database 
called miRBase (http://www.mirbase.org/) that is the primary online 
repository for all miRNA sequences and annotation. To date, the 
current release (miRBase 18) contains 18226 entries representing 
hairpin precursor miRNAs, expressing 21643 mature miRNA products, 
in 168 species, and over 19000 distinct mature miRNA sequences. The 
miRNA field is rapidly growing, considering that over 2000 miRNA 
sequences have been already described in vertebrates, flies, worms, 
plants, and even in viruses.
Cardiac stem cells or, which is better, Cardiac Progenitor Cells 
(CPC) are adult multipotent cells able to differentiate into the four main 
cardiac lineages: myocytes, Smooth Muscle Cells (SMC), Endothelial 
Cells (EC) and cardiac fibroblasts. They have been isolated and 
described for the first time by the research group of Piero Anversa in 
2003 [7]. They are self-renewing (able to maintain the undifferentiated 
state even after many cell cycles), clonogenic (able to expand in culture 
after plating one cell per well), and in vivo they are located inside cell 
niches with feeding cells [8]. 
Many research protocols have been developed to isolate CPCs 
from adult myocardium. Most of the research groups sorted c-Kit or 
Sca-1 positive cells after tryspin and collagenase II tissue digestion 
[7,9-12]. Messina and colleagues [13] used cells migrating out from 
cardiac tissue explants and grown in suspension as “cardiospheres”. 
Our research group has also been involved in CPC research; we are 
able to isolate these adult progenitors by slow tissue digestion, mild 
trypsinization and differential adhesion without cell sorting [14]. Using 
this mild protocol it is possible obtain a cell population with 96% c-Kit 
positive cells [15]. This population is also positive to Sca-1 and MDR-1 
(unpublished data), as described by Srivastava and colleagues [16] in 
a recent paper. Their differentiation potential have been evaluated by 
many research groups [9,12-14], but the complete differentiation and 
creation of a small piece of myocardium have never been demonstrated 
both in vivo and in vitro. These cells may be considered “progenitor” 
cells because they are immature committed proliferating cells able 
to differentiate into only one of the four above-mentioned lineages 
(myocyte, SMC, EC or cardiac fibroblasts) [16]. 
The discovery of c-Kit-positive CPCs that reside in the heart 
has definitely changed the knowledge about myocardial biology. 
The acceptance of the idea that the heart may regenerate has been 
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problematic and subjected to criticism. Myocyte death is a normal 
event that occurs during human heart diseases. In order to maintain 
heart vitality, myocyte death has to be accompanied by myocyte 
regeneration: this is the principle of homeostasis [17]. The identification 
of CPCs has generated several doubts about their role in spontaneous 
cardiac regeneration after damage. The fact that resident human CPCs 
have limitations in reconstructing cardiomyocytes after infarction 
is considered as the proof that the heart is a post-mitotic organ and 
terminally differentiated [18]. This could be explained thinking that 
CPCs, which are present throughout the infarcted myocardium, die by 
apoptosis and necrosis as the other cells during heart failure [18].
To differentiate CPCs into cardiomyocytes is quite difficult, 
and many research groups are trying to enhance both their degree 
of differentiation and the number of differentiated cells in order to 
substitute a damaged myocardium. There are two clinical trials ongoing 
in USA both using injected CPCs (SCIPIO [19] and CADUCEUS 
[20]). Data are encouraging, and demonstrate the paracrine potency, 
engraftment efficiency and therapeutic potential of these cells. Data 
suggest that CPCs delivered as the three-dimensional (3D) form of 
“cardiospheres” are more efficient [21]. The authors are now trying to 
find a 3D scaffold to deliver more efficiently these cells into a damaged 
myocardium [21]. 
A safe and standardised protocol to implant CPCs is necessary, 
but what it is really needed is to drive cell differentiation towards the 
myocardial phenotype. In order to develop a pre-clinical model which 
may lead to the most efficient myocardial differentiation of CPCs, we 
may use our knowledge about miRNA function, miRNAs involved 
in heart development, and the experiments on miRNA-driven CPC 
differentiation. The aim of the present review is to give an overview 
of miRNA function, target prediction, their involvement in heart 
development and the recent literature on CPC-expressed miRNA.
How do miRNAs Work?
miRNAs have been proposed as “micromanagers” of gene 
expression, because they might act as on-off switches to eliminate 
mRNAs that should not be expressed in a specific cell type or at a 
specific moment. They also can regulate mRNAs abundance, adjusting 
levels within physiological range [22].
miRNA genes are localised either in independent units, with their 
own promoter, or in introns (intronic miRNAs) of protein coding genes 
[23]. They are transcribed as pri-miRNA, processed and transformed 
into pre-miRNA inside the nucleus and translocated to the cytoplasm 
by the nuclear transport receptor Exportin-5 (Figure 1). The miRNA 
maturation process occurs in the cytoplasm; two strands are released: 
the stand with less stability at 5‘-end (typically a GU pair instead of 
GC pair) is loaded onto RISC, whereas the other strand, the passenger 
(miRNA*), is released (Figure 1) [24].
According to the official nomenclature, the term “miRNA*” 
indicates the miRNA strand which is weakly expressed. If it is not 
known which strand (miRNA-5p or miRNA-3p) is more expressed 
than the other, usually it is indicated “miRNA-5p” or “miRNA-3p” 
depending on the position on the genome (5’ or 3’-arm of the hairpin).
At first it was thought that miRNA* was degraded soon after 
its release. However, many evidences demonstrated that miRNA* 
molecules are often present at physiologically levels [25], and that they 
have many biological roles, for example miR-378* has been identified 
as a molecular switch in breast cancer cells [26], and miR-155* 
(together with miR-155) is involved in regulating human Plasmacytoid 
Dendritic Cell (PDC) activation [27]. Furthermore, substantial fraction 
of miRNA* species are stringently conserved over vertebrate evolution; 
they exhibit greatest conservation in their seed regions, and define 
complementary motifs whose conservation across vertebrate 3′-UTR 
evolution is statistically significant [28].
Moreover, it was found that a significant fraction of pre-miRNA 
hairpins produces miRNA* species whose seed sequence recognizes 
3’UTR target site. That means that miRNA* are not only inactive 
products of miRNA cleavage, but they also inhibit or regulate target 
genes [25].
The role of miRNAs inside the cell is to interact with their mRNA 
targets by base pairing. In plants, most miRNAs base pair to mRNAs 
with perfect complementarity, inducing mRNA degradation by a 
cleavage in the middle of the miRNA-mRNA duplex [29].
In the case of metazoans, generally, base-pairing between miRNA 
and its target is imperfect [30]. The region responsible of this interaction 
is called “seed sequence” and it corresponds to the nucleotide 2 to 8. 
Just for thermodynamic reasons, an A nucleotide across position 1, and 
an A or U across position 9, improve the site efficiency, even if they 
Figure 1: miRNA biogenesis. miRNAs are first transcribed as long primary 
miRNA transcripts (pri-miRNAs) by RNA polymerase II inside the nucleus. 
Pri-miRNA contains a stem-loop structure, a cap at 5’-end and a poly-A 
tail at 3’-end [74]. Then, pri-miRNA is processed by an enzymatic complex 
called “microprocessor”, to generate molecules 70-100 nt in length (pre-
miRNA) [77]. Pre-miRNA hairpins are recognised by Exportin-5 (Exp-
5) which allows the passage into cytoplasm, where Dicer creates a 22 nt 
small RNA duplex. In the cytoplasm, Dicer associates with ds-RNA-binding 
proteins, like transactivation-response element RNA-binding protein (TRBP) 
and p53-associated cellular protein (PACT) [78,79]. The helicase activity of 
Dicer unwounds the RNA duplex, one of the strands preferentially bind to 
Argonaute (Ago), and the effector complex “RNA induced silencing complex” 
(RISC) is generated [80]. The strand with less stability at the 5’-end is loaded 
onto RISC, whereas the other strand, the passenger (miRNA*), is released 
[24].
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do not need to base pair with miRNA nucleotides [31]. Furthermore, 
there must be complementarity to the miRNA 3’ half to stabilise the 
interaction, even if mismatches and bulges (structural motifs formed 
following a mismatch in the miRNA: mRNA heteroduplex) are 
tolerated in this region. If the matching with seed region is not perfect, 
there should be a good base-pairing to residues 13-16 of the miRNA to 
obtain a good stability [30,32].
There are many factors that influence the site efficiency, among 
which an AU-rich neighbourhood and, in case of long 3’UTRs, a 
position not so far away from the poly-A tail or the termination codon, 
in order to make binding sites more accessible [30,33]. In contrast to 
these rules, there are many cases in which a bulged nucleotide in the 
seed region is required for an efficient miRNA-mediated repression 
[34].
Typically, more than one miRNA binding site is present on 3’UTR 
of mRNA target and multiple sites for the same or different miRNAs are 
required for effective repression [30-33]. When they are localised close 
to each other they act cooperatively providing a stronger repression 
[30,31].
miRNAs act either inhibiting mRNA translation or inducing the 
degradation of the target. When the association miRNA-mRNA target 
exhibits several mismatches and bulges, it results in a reduced efficiency 
of translation rather than in a decrease in mRNA abundance [35]. The 
inhibition of mRNAs translation can occur at the initiation or post-
initiation step. In repression at the initiation step, Ago2 protein is the 
main actor: it has a Cap-binding like domain (MC) which bind the m7G 
cap of mRNA precluding the recruitment of eIF4E and, therefore, the 
assembly of the translation complex [36].
For the repression at post-initiation step a drop-off model is 
proposed: miRNAs render ribosome prone to premature termination 
of translation [37]. When miRNAs bind with a strong complementarity 
to their target, the mRNA degradation is induced by deadenylation 
in 3’→5’ direction catalysed by the exosome, or by the removal of the 
cap followed by 5’→3’ degradation catalysed by the exoribonuclease-1 
(XRN1) [34].
Degradation or, at least, its final steps, seems to occur in Processing 
bodies (P-bodies), that are granules localised in the cytoplasm enriched 
in mRNA-catabolyzing enzymes and translational repressors [38,39]. 
P-bodies are also enriched in Ago proteins and miRNAs. Originally they 
were considered as being primarily involved in mRNA degradation, 
but now it is clear that P-bodies are also temporary sites of storage of 
repressed mRNAs [34].
In particular situations, like following a stress, the mRNA 
sequestration in P-bodies can be irreversible and it can be released and 
translated after the interaction with polysomes [40].
Studies that look at a better understanding of miRNAs function 
are coming out everyday and many models are continuously proposed.
miRNA Prediction Target
To appreciate the significance of a change in miRNA levels during a 
particular cellular process, the identification of their own mRNA targets 
is crucial. To achieve this purpose many computational prediction 
target tools, based on specific algorithms, have been developed. The 
most widely utilized engines are miRanda, TargetScan and PicTar 
(summarised in Table 1). They are based on algorithms which rely on 
base-pairing between “seed sequence” of the miRNA and the 3’UTR 
sequence of the mRNA target but miRNA target sites are localised also 
within the coding region of a gene even if at much lower frequency. 
Each engine uses different algorithms to establish the alignment score.
MiRanda calculates the alignment score as the sum of match and 
mismatch scores, including G:U wobbles and gap penalties. Since 
sequence conservation is a strong indication of functional constraints 
in evolution, miRanda prediction software also considers the degree 
of evolutionary conservation of the targeted sequence and its position 
in 3’UTRs of human, mouse and rat genes [41]. TargetScan prediction 
software applies an alignment score for Watson-Crick (W-C) base-
pairing in the seed sequence (nucleotides 2-7) of the miRNA to 
its target and also base-pairing beyond the seed sequence that can 
compensate for mismatches in the seed. It also recognises a conserved 
adenosine at the first position and/or a W-C match at position 8, and 
considers the degree of conservation using three different levels: highly 
conserved between human, rat, mouse, dog, and chicken; conserved 
between human, mouse, rat, and dog; poorly conserved among any 
combination of species [30,42].
The third target prediction software is PicTar that takes into 
account a perfect W-C base paired 7 nucleotides seed (1-7 or 2-8) 
allowing mismatches if the free binding energy does not increase, the 
binding energy of the entire miRNA-mRNA duplex, and the degree 
of conservation of targeted sites between all the species (chimpanzee, 
pufferfish and zebrafish) [43].
Another important criterion that should be considered during 
miRNA target prediction is the accessibility of the target site. In fact 
when the target site is localised in a closed stem structure, the inhibition 
by miRNA is not allowed. For this reason prediction software, 
called Probability of Interaction by Target Accessibility (PITA) was 
designed; which allows prediction of target sites by first searching for 
complementary seed sequences, and then calculating the free binding-
energy after subtracting the energy used to unwind any predicted 
secondary structure [44,45].
However, the prediction algorithms used in the above mentioned 
softwares and databases do not consider the concentration of miRNAs 
inside the cell, the real accessibility of the target sequence or other 
factors which may modulate miRNA-target interactions, because they 
consider only the conventional target prediction rules based on base-
pairing. A false-positive rate of at least 40% must be considered [46]. 
Table 1: The most widely utilized engines for computational miRNA prediction target.
Prediction 
Target Tool Web Site Algorithm used
miRanda www.microrna.org The alignment score is the sum of match and mismatch scores, including G:U wobbles and gap penalties. The degree of evolutionary conservation is considered.
TargetScan www.targetscan.org Applies an alignment score for W-C base-pairing in the seed sequence and beyond it. Recognizes a conserved adenosine at the first position and/or a W-C match at position 8. Considers three degree of conservation.
PicTar www.pictar.mdc-berlin.de
Considers a perfect W-C base paired 7 nucleotides seed (1-7 or 2-8)allowing mismatches if the free binding energy does not 
increase, the binding energy of the entire miRNA-mRNA duplex, and the degree of conservation of targeted sites between 
all the species 
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miRNAs and Stem Cells 
miRNAs are involved in several physiological and pathological 
processes as development, apoptosis, cell differentiation, metabolism 
and cancer and they are often tissue-specific. Increasing evidences 
suggest that miRNAs are also involved in regulating cell renewal and 
differentiation. Several studies have demonstrated that the transition 
from the stemness state towards the differentiated one is regulated by 
epigenetic mechanisms as chromatin remodelling and changes in DNA 
and histone modifications [47].
miRNAs are considered epigenetic modulators of mRNA 
degradation and protein translation. The idea that they can regulate 
stem cell maintenance and induce cell fate decision is increasingly 
spreading [47]. Several evidences demonstrate that miRNAs tightly 
control Embryonic Stem Cell (ESC) self-renewal and differentiation 
state. Experiments on Dicer or DGCR8 deletion, performed in mouse 
and human ESC, confirmed a role of miRNAs in differentiation: the 
global loss of miRNAs resulted in proliferation and differentiation 
defects of ESC [48]. Other studies identified specific sets of miRNAs, 
like miR-290 cluster, which contains several members as miR-291, 
miR-292, miR-293, miR-294, miR-295, and miR-302 family, formed by 
miR-302a, miR-302b, miR-302c, miR-302d and miR-367, as “ESC-cell 
cycle regulating clusters” because they repress key regulators of the cell 
cycle to ensure a rapid G1-S transition [49].
miRNAs are involved in signalling pathways leading to cell lineage 
commitment. For example the two miR-125 isoforms (miR-125a and 
miR-125b) may inhibit SMAD4 expression in human ESCs regulating 
neuronal commitment [50]. In particular, treatment with activin and 
BMP4 blocks the activity of miR-125a and miR-125b, promoting 
significant levels of SMAD4 expression. This induces phosphorylation 
of SMAD2/3 and SMAD1/5, and promotes self-renewal or MP-
induced lineages, as neural crest and epidermis [50]. When activin and 
BMP receptors are inhibited, miR-125 isoforms are expressed, SMAD4 
is down-regulated and ESC are irreversible committed towards the 
neural lineage [50].
In another study, the authors suggest that miR-181a*, miR-302a 
and miR-456 have a role in maintaining the undifferentiated state 
of the Primordial Germ Cell (PGC) and the Blastodermal Cell (BC) 
in chickens [51]. In PGC miR-181a* inhibits the meiotic transcript 
NR6A1 and the somatic HOXA1, modulating the different regulatory 
pathways for meiosis in chicken early germ cells [51]. In PGC and BC 
miR-302a and miR-456 silence the expression of somatic genes (as Sex 
determining region Y-box, SOX11), regulating pluripotency [51]. The 
signalling pathways through which miR-181a*, miR-302a and miR-456 
regulate pluripotency in chicken needs further investigation. 
miRNA are effectors of preconditioning signals. Preconditioning is 
a powerful cytoprotective stimulus which can be used to promote stem 
cell survival upon implantation. Ischemia preconditioning significantly 
reduces cell apoptosis in Mesenchymal Stem Cells through activation 
of Akt and ERK1/2, and through nuclear translocation of the hypoxia-
inducible factor-1α (HIF-1α). This nuclear factor positively regulates 
miR-210 transcription, and its up-regulation inhibit the expression of 
FLASH/Casp8ap2 gene, member of the apoptosis signalling complex 
that activates Caspase-8 and promote Fas-induced apoptosis [52]. 
The same authors demonstrated that miR-21 is up-regulated in IL-
11 preconditioning experiments of skeletal myoblasts in a rat model of 
myocardial infarction. Diaxozide preconditioning of skeletal myoblasts 
activates IL-11 synthesis, which in turn activates miR-21 up-regulation 
via ERK1/Stat3 signalling, promoting stem cell survival [53].
Recently a new role for miRNAs has been proposed: this small 
non-coding mRNAs may be manipulated to reprogram stem cells 
for stem cell therapy. This hypothesis has been proposed after that 
it has been demonstrated that miR-302/miR-367, ESC specific, are 
expressed in early embryonic development and then rapidly decline 
after differentiation [54,55]. Hence, many laboratories developed miR-
302/367 mediated induced Pluripotent Stem Cells (iPSC) [56,58].
This kind of iPSC are claimed to be more safe because oncogenes, 
as c-Myc, are not over-expressed. All the genes down-regulated or all 
the epigenetic changes induced by these two miRNAs are not known, 
but the preliminary experiments on miRNA-reprogrammed iPSC 
demonstrated that they are less tumorigenic than the conventional 
iPSC [56,57].
miRNAs may be delivered in vitro as small molecules using 
lipofectamine or similar substances, considering that they are similar 
to siRNAs. A more stable transfection may be achieved creating an 
artificial expression vector that can both generate functional mature 
miRNAs and maintain their expression in vitro and in vivo. miRNA 
may diffuse from a donor cell to stem cells through gap junctions, 
in co-cultures with engineered donor cells. Or, which is the more 
stable system, miRNA may be delivered along with reporter genes 
or hormone activated promoters using an artificial intron (SpRNAi) 
placed between two exons. To date the most efficient method to 
introduce reprogramming factors into cells is viral transfection, but 
since this may result in integration in exogenous genes, this may not be 
used in clinical trials [57].
miRNA and Heart Development
Apart from studies on the importance of miRNAs in ESC 
differentiation, many studies have been conducted to shine a light 
on the importance of miRNAs in heart development. It has been 
demonstrated that in zebrafish miR-138 is fundamental for the correct 
development of ventricles and for cardiomyocytes maturation. The 
loss of miR-138 leads to the expression in ventricular region of the 
genes whose expression is normally restricted to the atrio-ventricular 
valve region and it induces a block of the ventricular cardiomyocyte 
differentiation [58].
The importance of miRNAs during cardiac development is 
confirmed by recent evidences. In a mouse model, the inactivation of 
Dicer in CPCs was lethal during embryogenesis at E12.5 [45]; mice 
KO for DGCR8 developed a dilated cardiomyopathy, died of heart 
deficiency in less than 31 days, and the expression levels of miR-1, miR-
133 and miR-208, cardiac specific, noticeably decreased [59].
The miRNAs most studied in heart development are miR-1 and 
miR-133, critical regulators of cardiac proliferation and differentiation 
(Figure 2) [60]. MiR-1 and miR-133 are encoded by a duplicated locus 
in the mammalian genome. They are expressed by a cluster called miR-
1-1/miR-133a-2 on the chromosome 2, and by a cluster called miR-1-2/
miR-133a-1 on the chromosome 18. However, miR-1-1 and miR-1-2, 
and miR-133a-1 and miR-133a-2, originated from different loci, have 
the same sequence [60]. Mi-206/miR-133b cluster is transcribed from a 
non-coding region on the chromosome 1. MiR-206 is skeletal muscle-
specific and shares with miR-1 the same seed sequence, but they differ 
for 4 nucleotides in the 3’-end. MiR-133b has the same seed sequence 
of miR-133a-1 and miR-133a-2, and it differs just for one nucleotide 
in 3’end [61].
MiR-1 is highly conserved among species: comparison of genomic 
sequences across species reveals that a 4.6 kilobase (kb) and 10.7 
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kb genomic region around miR-1-1 and miR-1-2, respectively, 
is conserved between human and mouse. Within the promoter 
regions there are several cis elements conserved between human and 
mouse that represent potential binding sites for the essential cardiac 
transcription factors Myocyte-specific enhancer factor 2C (Mef2C), 
Serum Responsive Factor (SRF), Nkx2.5 and Gata4 [62]. In the heart, 
the miR-1 expression is tightly dependent on SRF [62]: mutation of the 
miR-1-1 SRF site abolishes miR-1 expression. Since miR-133 is located 
on the same locus of miR-1, it is also under the SRF control; moreover, 
miR-133 inhibits the expression of SRF through a negative regulating 
loop [60,63]. MiR-133a-1/miR-1-2 and miR-133a-2/miR-1-1 genes 
are demonstrated to be expressed in the ventricular myocardium and 
interventricular septum from E8.5 until adulthood [62,64].
Deletion experiments have highlighted the importance of miRNAs 
in cardiac maturation. For example, in mouse, deletion of the gene 
coding for miR-1-2 or for miR-133 leads to alterations during 
cardiogenesis like the failure of ventricular septation that results in 
death within few hours after birth [45,65]. Both miR-1-1 and miR-1-
2 are more expressed in the outflow tract of the heart which derives 
from the secondary heart field. It has also been seen that miR-1 is 
fundamental for cardiomyocyte differentiation, thus it has anti-
proliferation effects. In fact miR-1 overexpression causes the loss 
of cardiomyocytes and cardiac hypoplasia which is lethal at E13.5. 
This event is due to the miR-1-mediated repression of Heart- and 
neural crest derivatives-expressed protein 2 (Hand2), an important 
transcription factor involved in cardiomyocytes proliferation [62]. The 
induction of the myogenic phenotype mediated by miR-1 is dependent 
from the repression of Histone Deacetylase 4 (HDAC4), that negatively 
regulates Mef2 [60,66]. 
About 50% of null mice for one of two loci of miR-1 dies from 
Ventricular-Septal Defects (VSDs) between late embryogenesis and 
birth, while a subset of mutant mice can survive to adulthood showing 
electrophysiological defects. On the other hand, complete ablation 
of miR-133 via double gene knockout induces cardiac defects during 
embryogenesis, and death one day after birth (P1 stage) showing 
dilated atria, and enlarged, engorged with blood, and containing 
thrombi hearts [65]. This suggests the occurrence of the defect in 
cardiac contractility.
In summary, the miR-1/miR-133 cluster is one of the main 
regulators of proliferation and differentiation of cardiac precursors.
miRNAs and Cardiac Stem Cell Therapy
miRNAs play a role not only in regulating ESC but also adult 
progenitor cell differentiation. At present only a few papers have been 
published on the expression of miRNAs in CPCs and a few on the first 
experiments to manipulate cell differentiation through miRNA over-
expression.
Up-regulation of cardiac miR-1, miR-133 and miR-208 has been 
detected in Nkx2.5 engineered canine CPCs [67]. A comparison 
between the miRNA expression pattern in neonatal and adult murine 
CPCs revealed a cohort of eight miRNAs that are up-regulated 
during the post-natal development that may justify differences in 
proliferation. In particular, a member of the miR-17-92 cluster, miR-
17, was identified as the most differentially expressed miRNA [68].
Recently, in our laboratory we have demonstrated the differential 
expression of miR-135a between bi-dimensionally and 3D cultured 
adult rat CPCs (unpublished data). We suppose that the 3D 
environment induces cells to differentiate and synthesize miR-135a 
and many sarcomeric proteins. The direct correlation between miR-
135a and sarcomere assembly must be elucidated. 
A few attempts have been made to manipulate CPCs for stem cell 
therapy. The overexpression of miR-1 or miR-499 promotes early 
occurrence of spontaneous beating areas upon differentiation of 
CPCs. In particular miR-1 over-expression induces a reduction in the 
proliferative rate and miR-499 leads to an increase in the expression 
of cardiac transcription factors responsible for cardiac differentiation 
[69]. MiR-499, upon migration from the donor cells, regulates 
the commitment of c-Kit-positive human CPCs favoring their 
differentiation into competent cells by repressing Sox6 and Regulator 
of differentiation 1 (Rod1) [70].
As for the studies on stem cell preconditioning and reprogramming, 
miRNAs have been used to improve homing, integration and survival 
of engraft CPCs in the infarcted myocardium. A pro-survival cocktail 
of miR-21, miR-24 and miR-221 was employed to improve cell viability 
and survival of Sca-1 positive CPCs both in vitro and in vivo (Figure 
3) [71]. 
Similarly human Sca-1 positive CPCs migration and necrosis may 
be reduced by miR-155 over-expression [72,73]. On the base of their 
previous findings, the authors demonstrated that the overexpression 
of miR-155 results in a block of human CPCs migration by targeting 
matrix metalloproteinase MMP-16, which is an activator of MMP-2 
Figure 2: MiR-1 and miR-133 in heart development. During cardiomyocites 
differentiation, expression levels of miR-1 and miR-499 increase. miR-1 
induces differentiation by inhibiting the expression of HDAC4, Delta like l (Dll1) 
and Hand2 which in turn regulate the expression of cardiac specific genes 
[60]. miR-499 negatively regulates the expression of Sox6 and Rod1  [70]. 
miR-133 inhibits differentiation inhibiting the expression of SRF, conversely 
promoting cell proliferation [60].
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and MMP-9 (Figure 3) [73,74]. This is the only experimental evidence 
on the feasibility to use a miRNA as a drug for human CPC implantation 
and survival for a therapeutic use.
Concluding Remarks
All the evidences mentioned above suggest that miRNAs play 
a fundamental role in regulating cell renewal, heart development, 
embryonic and adult stem cell differentiation, and stem cell migration. 
These small RNAs can influence the expression of cluster of genes by 
pairing the target sequence. It is widely accepted that miRNAs can 
inhibit the expression of the target genes, but it is not known if pairing 
may also enhance the expression of some other target genes. 
The research group of Prof. Rassoulzadegan studying the 
effects of miR-124 described also a phenomenon which they called 
paramutation, which is an RNA-mediated hereditary epigenetic 
change in the chromatin structure of the promoter of Sox9 [75,76]. 
Differently from the mechanisms described in this review, this miRNA 
mediated phenomenon induces the over-expression of Sox9 and not 
its repression [76]. Our knowledge on miRNAs needs to be improved 
as they appear to be fine regulators of many processes inside the cells 
rather than switching the genes on or off. 
Even if the molecular mechanism underlying miRNAs is not 
completely understood, many research groups are trying to use these 
small non-coding RNA molecules in in vitro and in vivo experiments on 
stem cells. These molecules may be useful in cardiac stem cell therapy 
because they can be easily synthesised, can be attached to biomaterials 
or surgery devices, can be used in nanotechnology and could really 
finely regulate stem cell differentiation in vivo upon implantation of 
undifferentiated stem cells. 
In cardiac tissue regeneration, nanoparticles bearing miRNAs or 
SpRNAi may be used to reprogram isolated CPCs in a biodegradable 
tolerated 3D scaffold. In this way, it would be possible to start 
reprogramming in vitro, and to continue in vivo obtaining the best 
efficiency in cell commitment and myocardial differentiation.
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